GlassScriptPhysician profile
Michael D Voiles
NPI 1881000107
$7,458.82
in general payments reported to CMS, 2019-2025
37 companies · $1,965 in 2025
The $1,965 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $242 · 2022: $1,577 · 2023: $1,621 · 2024: $2,054 · 2025: $1,965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,593 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,593.10 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $938.17 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $773.32 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $738.23 | 2022-2025 | Caplyta |
| Pfizer INC. | $556.33 | 2023-2025 | |
| Abbvie INC. | $476.63 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $380.68 | 2022-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $373.01 | 2022-2025 | Rexulti, Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $365.80 | 2022 | |
| Astellas Pharma US INC | $323.30 | 2023-2025 | Veozah, Myrbetriq |
| Neurocrine Biosciences, INC. | $306.13 | 2022-2025 | Ingrezza |
| Lilly USA, LLC | $298.49 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Otsuka America Pharmaceutical, INC. | $261.63 | 2022-2025 | Rexulti, Abilify Maintena |
| Amgen INC. | $256.18 | 2022-2025 | Evenity, Otezla, Repatha |
| Alkermes, INC. | $237.65 | 2022-2025 | Vivitrol |
| Revance Therapeutics, INC. | $178.88 | 2025 | Daxxify |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $147.28 | 2023-2025 | |
| Axsome Therapeutics, INC. | $126.92 | 2022-2023 | Sunosi, Auvelity |
| Sk Life Science, INC. | $72.46 | 2022-2023 | |
| Collegium Pharmaceutical, INC. | $63.93 | 2024-2025 | Belbuca |
| Xeris Pharmaceuticals, INC. | $62.86 | 2023-2025 | Keveyis |
| Bayer Healthcare Pharmaceuticals INC. | $50.67 | 2025 | |
| Biogen, INC. | $47.41 | 2021-2022 | |
| Phadia US INC. | $41.23 | 2023 | Immunocap |
| Baxter Healthcare | $39.69 | 2022 | |
| Welch Allyn | $39.69 | 2021 | |
| Harmony Biosciences LLC | $38.00 | 2023 | Wakix |
| Cranial Technologies, INC | $36.16 | 2024-2025 | Doc Band |
| Phathom Pharmaceuticals, INC. | $30.52 | 2024-2025 | Voquezna |
| Bardy Diagnostics, INC. | $30.20 | 2021 | |
| Janssen Pharmaceuticals, INC | $27.63 | 2025 | Spravato |
| Indivior INC. | $24.32 | 2025 | Sublocade |
| Genentech USA, INC. | $23.28 | 2021-2024 | Xolair |
| Exact Sciences Corporation | $22.69 | 2025 | Cologuard Collection Kit |
| Eisai INC. | $22.15 | 2025 | |
| Aimmune Therapeutics, INC. | $19.84 | 2024 | |
| Supernus Pharmaceuticals, INC. | $13.92 | 2021 | |
| Braeburn INC. | $13.54 | 2025 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Voiles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.